Central Adiposity Gives Greater Insight Into CV Risk Than BMI
Waist-based measurements paint a more comprehensive picture and can reclassify patients’ cardiovascular risk, a large dataset suggests.
Waist-based measurements of body composition add diagnostic and prognostic value over conventional body mass index (BMI) categories when used to classify patients’ cardiovascular risk, according to a new study.
Led by Zeina A. Dardari, PhD (Johns Hopkins Medicine, Baltimore, MD, and Indiana University, Indianapolis), researchers compared the performance of both waist circumference (WC) and waist-to-hip ratio (WHR) to that of BMI in a combined dataset of a quarter million participants.
One in five people with normal BMI had high WHR, suggesting “hidden elevated risk,” they say. Yet WHR was low for 45% of people considered overweight based on BMI, suggesting their risk might be lower than anticipated.
The idea that “BMI is an imperfect measure of metabolic risk is not new per se,” senior author Michael J. Blaha, MD (Johns Hopkins Medicine), told TCTMD.
What is novel about this study, Blaha said, is that it harnesses the strength of the Cross-Cohort Collaboration (CCC). By bringing numerous “high-quality prospective cohorts together,” investigators had “unprecedented statistical power to be able to look at some questions that you can’t look at in smaller studies,” he explained. This enabled them to dig into various permutations of BMI, WC, and WHR across subgroups, with the goal of better understanding where the various measurements “might make a difference to us clinically.”
The work is also timely, said Blaha. With the advent of glucagon-like peptide-1 (GLP-1) receptor agonists, physicians are now able to treat adiposity and reduce cardiovascular risk. At the same time, the Lancet Commission is urging a rethink on how best to define obesity.
Fatima Cody Stanford, MD (Massachusetts General Hospital and Harvard Medical School, Boston), who served on the Lancet Commission, agreed the study’s scale and clarity of risk reclassification are novel. “The central message is that BMI alone can miss meaningful differences in cardiovascular risk,” she wrote in an email to TCTMD.
“The results are not entirely biologically surprising; we have known that body fat distribution matters,” Stanford added. “What is striking is the consistency of the findings across outcomes such as heart failure, atrial fibrillation, coronary heart disease, stroke, and mortality. It reinforces that two people with the same BMI can have very different cardiometabolic risk profiles.”
Central adiposity in the form of excess visceral fat is “associated with insulin resistance, unfavorable lipid changes, elevated blood pressure, chronic inflammation, and activation of hormonal pathways that contribute to cardiovascular disease. It also appears to promote vascular dysfunction and atherosclerosis,” Stanford explained.
“In practical terms, central fat distribution is not simply a cosmetic or weight-related issue,” she added.
Waist-Based Metrics
For the study, published online August 11, 2026, in JACC, Dardari et al included 259,388 participants from 15 datasets of the CCC. Median follow-up lasted 20.0 years, with both WC and WHR measurements available for most individuals. Investigators looked into numerous forms of CVD: time to MI, stroke heart failure, atrial fibrillation, total coronary heart disease, total CVD, coronary heart disease mortality, and CVD mortality, as well as all-cause mortality.
Among those with normal weight based on BMI, 5% had high WC and 18% had high WHR, as compared with 39% and 40%, respectively, of those considered overweight. Conversely, of those with obesity based on BMI, 9% had low WC and 45% had low WHR.
Higher values for WC and WHR were associated with greater prevalence of hypertension, hyperlipidemia, diabetes, current smoking, and having less than a high school education. People with higher versus lower WC were more apt to be women and less likely to currently drink alcohol, and tended to have higher BMI. Those with higher versus lower WHR, on the other hand, were more likely to be men and to report current alcohol use, with no differences in mean BMI.
For people with normal weight or overweight, high WC or WHR imparted greater risks ranging from 15% to 50% across the various cardiovascular outcomes. The largest increases were seen for all-cause death and cardiovascular disease.
For people with obesity, low WC translated into lower risk of all-cause mortality but no other differences.
With obesity but low WHR, however, patterns differed by sex. Women in this category had a higher risk of all outcomes than did women with both normal weight and low WHR. Men in this category only saw increased risk of atrial fibrillation compared with men who had both normal weight in low WHR.
The investigators also calculated the population impact of considering waist-based measurements on top of BMI. Among people with obesity, 49% of heart failure events, 46% of atrial fibrillation events, and 36% of coronary heart disease mortality were attributable to elevated WC.
“Relying solely on BMI may result in misclassification of cardiovascular risk across a wide range of cardiovascular outcomes,” they conclude. “We encourage clinicians to consider central adiposity distribution across the entire BMI spectrum when evaluating cardiovascular risk in primary prevention settings.”
‘Tip the Scale’ Away from BMI?
Kershaw V. Patel, MD (Houston Methodist DeBakey Heart and Vascular Center, TX), and Neela D. Thangada, MD (Northwestern University, Chicago, IL), say that the field’s “understanding of obesity as a chronic condition and modifiable risk factor for CVD is increasing as we learn more about different measures of adiposity.”
These new results confirm that “abdominal fat burden provides incremental prognostic information for risk of fatal and several nonfatal CVD events across BMI levels,” they note in an accompanying editorial.
Patel and Thangada point out that the divergence between measures of body fat could have implications for patients on GLP-1 receptor agonists. Citing data from an analysis of the SELECT trial, they point out that semaglutide’s cardioprotective effects seem to be tied more closely to decreases in central adiposity than to weight loss.
Still, the best way to integrate weight-based metrics into clinical practice isn’t yet known, they emphasize. “Does incorporation of these measures of central adiposity into existing models meaningfully improve CVD risk assessment? Are longitudinal changes in measures of central adiposity prognostically important and how frequently should WC and WHR be measured?” Although the new findings may start to “tip the scale” away from BMI, they add, it remains the most common way to measure obesity.
The purpose is not to stigmatize patients or reduce health to a number. It is to identify potentially modifiable cardiometabolic risk that BMI alone may miss. Fatima Cody Stanford
For clinicians, Stanford suggested, “I would consider waist circumference the most practical first step, with WHR as a useful complementary measure when a more nuanced assessment of body fat distribution is needed.”
BMI, on the other hand, is still a quick, inexpensive screening tool that can be used to identify patients who might “benefit from a more complete assessment of adiposity-related health risks,” she advised. “However, BMI should not be used as a stand-alone measure of cardiovascular risk. It does not distinguish fat from lean mass, nor does it indicate where fat is stored.”
Based on the study results, Blaha said, “what we’re really pushing towards is [that taking] at least a single measure of visceral adiposity in addition to BMI is going to really improve your risk classification of these patients.”
Moving away from BMI as the main measure will “take a lot of discussion at the highest levels. . . . It’s so entrenched in so many guidelines, definitions, and entry criteria for trials that it’s unlikely to go away, which is why this paper is structured as more of what you can learn in addition to BMI rather than trying to supplant it.”
Stanford agreed that it may take time and effort to build momentum towards waist-based measurements. “BMI is already embedded in electronic health records, clinical workflows, public-health messaging, and insurance criteria. It requires only height and weight, which are routinely obtained at nearly every visit. Waist measurement adds another step, requires appropriate clothing and patient privacy, and is not always performed using a standardized technique,” she said. Moreover, there are questions about the best cut points in relation to age, sex, and race/ethnicity.
All of this, however, shouldn’t deter doctors from adopting “a simple measurement that can add meaningful context to BMI,” stressed Stanford. “Most importantly, we need to communicate that the purpose is not to stigmatize patients or reduce health to a number. It is to identify potentially modifiable cardiometabolic risk that BMI alone may miss.”
Caitlin E. Cox is Executive Editor of TCTMD and Associate Director, Editorial Content at the Cardiovascular Research Foundation. She produces the…
Read Full BioSources
Dardari ZA, Yao Z, Zhang J, et al. Risk reclassification beyond BMI by waist circumference and waist-to-hip ratio across 9 cardiovascular outcomes: results from the Cross-Cohort Collaboration. JACC. 2026;88:670-684.
Patel KV, Thangada ND. Tipping the scale away from body mass index? Waist-based measures of adiposity and cardiovascular disease risk. JACC. 2026;88:685-687.
Disclosures
- Dardari reports no relevant conflicts of interest.
- Blaha has served on advisory boards for Novo Nordisk, Bayer, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Genentech, Idorsia, Agepha, Vectura, and NewAmsterdam Pharma.
- Patel has served as a consultant to Novo Nordisk and on the advisory board for Roche Diagnostics, and he has participated on a clinical trial committee for a study sponsored by Retension Pharmaceuticals.
- Thangada has received research support from the American Heart Association.
- Stanford reports serving on the Lancet Commission.
Comments